open access
Tumefactive demyelinating lesion in patient with neuromyelitis optica spectrum disorder
- Department of Neurology, Gazi University Faculty of Medicine, Ankara, Turkey
- Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey
open access
Abstract
Abstract
Keywords
tumefactive demyelinating lesion, longitudinal extensive transverse myelitis, neuromyelitis optica spectrum disorders, rituximab
Title
Tumefactive demyelinating lesion in patient with neuromyelitis optica spectrum disorder
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Letter to the Editors
Pages
285-287
Published online
2022-06-21
Page views
4583
Article views/downloads
542
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2022;56(3):285-287.
Keywords
tumefactive demyelinating lesion
longitudinal extensive transverse myelitis
neuromyelitis optica spectrum disorders
rituximab
Authors
Tuğberk Andaç Topkan
Okan Sokmen
Belgin Kocer
Rana Karabudak
Pinar Uyar Gocun
- Wingerchuk DM, Banwell B, Bennett JL, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2): 177–189.
- Tomizawa Y, Nakamura R, Hoshino Y, et al. Tumefactive demyelinating brain lesions with multiple closed-ring enhancement in the course of neuromyelitis optica. J Neurol Sci. 2016; 361: 49–51.
- Wayne Moore GR, Stadelmann-Nessler C. Demyelinating Diseases . In: Love S, Perry A, Ironside J, Budka H. ed. Greenfield's neuropathology. 9th ed. Boca Raton: CRC Press; 2015 [chapter, London 2015: 1297–1413.
- Kalinowska-Lyszczarz A, Tillema JM, Tobin WO, et al. Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis. Mult Scler. 2022; 28(3): 441–452.
- Almekhlafi MA, Clark AW, Lucchinetti CF, et al. Neuromyelitis optica with extensive active brain involvement: an autopsy study. Arch Neurol. 2011; 68(4): 508–512.
- Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord. 2017; 14: 72–79.
- Sempere AP, Feliu-Rey E, Sanchez-Perez R, et al. Neurological picture. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. J Neurol Neurosurg Psychiatry. 2013; 84(12): 1338–1339.